Is a PEGylated Protein Considered a Biobetter Biologic or Biosimilar Drug?
The FDA’s consideration of a biosimilar drug could open up biologic drug research. Learn how you can innovate with our PEGylation products!
Read more
Read more
Novel PEG hydrogel as 3D synthetic extracellular matrix (ECM) for organoid culture
A recent article published in the leading scientific journal of Nature (Designer matrices for intestinal stem cell and organoid culture, Matthias P. Lutolf et al from the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland, Nature, Published online 16 November 2016, doi:10.1038/nature20168) reported the first intestinal and colorectal cancer organoid culture in fully defined extracellular matrix […]
PEGfilgrastim (Neulasta) Approved for Treatment of Acute Radiation Syndrome
In November 2015, the Food and Drug Administration approved the use of Amgen’s pegfilgrastim (Neulasta) to increase the survival of people acutely exposed to high-dose radiation that damages the bone marrow, which will improve access to the drug in the event of a public health emergency such as a nuclear power plant accident or terrorist […]
The next stop for PEGylated protein drugs: Biosimilar
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor analog filgrastim. It serves to stimulate the level of white blood cells. Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours). Pharma Companies & PEGylated Drug Development Multiple major pharma companies have been busy […]